GlobeNewswire by notified

PharmaLedger Association Launches Digital Trust Ecosystem in Healthcare

Share

BASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- The PharmaLedger Association™ (PLA), a not-for-profit based in Switzerland, announces the endorsement of its 3-year strategic plan to implement and promote a Digital Trust Ecosystem in healthcare (DTE-H) at its Annual General Meeting held in Lucerne, Switzerland on 1 March 2023. The member organizations also confirmed the appointment of eight Directors to its board, delivering on PLA’s core value of “Ecosystem Leadership.”

Representing the diversity of healthcare, PLA’s founding members comprise of large and small pharmaceutical companies, research organizations, patient representative organizations, non-profit organizations, technology, and healthcare service providers. PLA has confirmed its mandate as a pre-competition umbrella organization delivering common and interoperable digital solutions in the areas of Product Trust, Decentralized Clinical Trials, and Supply Chain Traceability.

  • Products & Project: In Q1 2023, PLA will release the first qualified product, electronic Product Information for implementation by its members.
    In Q2 2023, the Association will continue with the development of new products in its innovation xLab, including of a product digital twin, decentralized identities, and verifiable credentials to facilitate visibility, security, traceability, and trust in all areas of healthcare.
  • Governance & Compliance: PLA will leverage its capability to develop, qualify, launch, and maintain products in healthcare’s highly regulated environment by ensuring continuous adherence to antitrust, intellectual property, data privacy, and Computerized System Assurance guidelines.

  • Ecosystem Engagement & Growth: The association will continue to onboard new members and engage with authorities, trade associations and standards development organizations, ensuring growth and financial viability.

  • Platform Technology & Security: PLA will focus on easing adoption of new solutions with its members and users while maintaining the cybersecurity benefits of its architecture.

The formation of PLA and the endorsement of its mission by diverse members of healthcare is a major milestone. This paves the way for delivery of widely trusted blockchain-based platforms with new open-source healthcare solutions to create value for patients and ecosystem stakeholders. PLA is grateful to its 20 founding members and invites all healthcare related organizations to learn more and engage towards the realization of a trusted Healthcare 4.0.

“Blockchain is a team sport. PLA has started with a diverse and strong team of members with a common vision and who believe in real change. With PLA we have the right vehicle, resources, and roadmap to take patients to a better place in healthcare,”Daniel Fritz, Executive Director, PharmaLedger Association.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

PLA is the result of the successful completion of the PharmaLedger research project, a €22 million, 30-member consortium with 12 large pharma companies and 18 public partners, funded under the European Union (EU) and European Federation of Pharmaceutical Industries and Associations (EFPIA)’s Innovative Health Initiative.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0682572a-b8ac-4b5b-885b-8af008287cff

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 202519.4.2024 18:43:36 CEST | Press release

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 19th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds due 2025 issued on 21 January 2020 (the “2025 Bonds”; ISIN: XS2105716554) to tender for purchase via a reverse bookbuilding process for cash any and all of their 2025 Bonds (the “Invitation”). Pharming announces the repurchase of €123.1 million of the 2025 Bonds, which represents 98.5% of the outstanding aggregate principal amount of the 2025 Bonds, on the basis of a final repurchase price per 2025 Bond equal to €100,000. In addition, the Company will pay accrued and unpaid interest from, and including, 21st January

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release

Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419

23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release

Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

HiddenA line styled icon from Orion Icon Library.Eye